corticosterone has been researched along with Osteonecrosis in 2 studies
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis." | 1.42 | Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. ( Cai, X; Cheng, C; Evans, WE; Janke, LJ; Jeha, S; Kamdem Kamdem, L; Karol, SE; Paugh, SW; Payton, MA; Pui, CH; Ramsey, LB; Relling, MV; Williams, RT, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramsey, LB | 1 |
| Janke, LJ | 1 |
| Payton, MA | 1 |
| Cai, X | 1 |
| Paugh, SW | 1 |
| Karol, SE | 1 |
| Kamdem Kamdem, L | 1 |
| Cheng, C | 1 |
| Williams, RT | 1 |
| Jeha, S | 1 |
| Pui, CH | 1 |
| Evans, WE | 1 |
| Relling, MV | 1 |
| Makado, S | 1 |
| Yamamoto, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
2 other studies available for corticosterone and Osteonecrosis
| Article | Year |
|---|---|
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2015 |
[Aseptic necrosis following the systemic administration of corticosteroid].
Topics: Corticosterone; Humans; Osteonecrosis | 1977 |